Palatin Technologies, Inc.

About Palatin Technologies, Inc.

Palatin Technologies is a biopharmaceutical company focused on discovering and developing novel therapeutics for patients with inflammatory and autoimmune conditions. They leverage the melanocortin system to design treatments that resolve harmful inflammation, providing a unique approach to allow affected tissues to heal.

Products & Services

VYLEESI (bremelanotide injection):A treatment offered by Palatin Technologies, with more information available on their dedicated website.

Pipeline Treatments:Focused on developing treatments for inflammatory and autoimmune diseases, starting with ocular conditions.

Specialties

Melanocortin system Inflammatory and autoimmune conditions Ocular conditions melanocortin receptor agonists MC4R agonists rare neuroendocrine diseases obesity inflammatory conditions autoimmune conditions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 18200000 MR: - FA: $18.2 million FAN: 18200000	D: 2025-11-12 FD: 2025-11-12	3 investors
2	RT: Public Offering T: - FT: Public Offering	A: 15800000 MR: - FA: $15.8 million FAN: 15800000	D: 2025-11-06 FD: 2025-11-06	5 investors
3	RT: Public Offering T: - FT: Public Offering	A: 1100000 MR: - FA: approximately $1.1 million FAN: 1100000	D: 2025-05-08 FD: 2025-05-08	3 investors
4	RT: Public Offering T: - FT: Public Offering	A: 11500000 MR: - FA: $11.5 million FAN: 11500000	D: 2025-05-07 FD: 2025-05-07	-
5	RT: Registered Direct Offering and Concurrent Private Placement T: - FT: Registered Direct Offering and Concurrent Private Placement	A: 4700000 MR: - FA: $4.7 million FAN: 4700000	D: 2025-02-07 FD: 2025-02-07	1 investors
6	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 3400000 MR: - FA: approximately $3.4 million FAN: 3400000	D: 2024-12-16 FD: 2024-12-16	1 investors
7	RT: Warrant Exercise T: - FT: Warrant Exercise	A: 6100000 MR: - FA: approximately $6.1 million FAN: 6100000	D: 2024-06-21 FD: 2024-06-21	1 investors
8	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2024-02-01 FD: 2024-02-01	-
9	RT: Registered Direct Offering T: - FT: Registered Direct Offering	A: 10000000 MR: - FA: approximately $10 million FAN: 10000000	D: 2024-01-30 FD: 2024-01-30	1 investors
10	RT: Non-dilutive T: - FT: Non-dilutive	A: 4700000 MR: - FA: 4.7 million FAN: 4700000	D: 2023-01-18 FD: 2023-01-18	-

Public Offering Latest

2025-11-12

$18.2M

3 investors (Pro only)

Public Offering 2025-11-06

$15.8M

Public Offering 2025-05-08

$1.1M

View 9 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Carl Spana

Chief Executive Officer, President, and Director

S

Stephen T. Wills

Chief Financial Officer, Chief Operating Officer, and Treasurer and Secretary

S

Stephen Slusher

Chief Legal Officer

J

John Dodd

Senior Vice President, Preclinical Development

J

James Hattersley

Senior Vice President, Business Development

R

Robert Jordan

Senior Vice President, Program Operations

View 7 more team members with Pro

Unlock Full Team Directory

Recent News